Exanta

For decades, the standards of antithrombotic therapy have been heparin and coumarin compounds, primarily warfarin (1). Other… Expand

Thrombosis is the leading cause of death from heart attacks and strokes. Warfarin (coumadin), the only marketed oral… Expand

It is rare for any drug introduced more than 50 years ago to remain unsurpassed today; yet the oral prevention and treatment of… Expand

INTRODUCTION The effect of the oral direct thrombin inhibitor (DTI) ximelagatran (Exanta, AstraZeneca) on the endogenous thrombin… Expand

Background Ximelagatran (Exanta™, AstraZeneca), an oral direct thrombin inhibitor for the prevention and treatment of… Expand

The oral direct thrombin inhibitor ximelagatran (Exanta, AstraZeneca) is rapidly absorbed, is efficiently bioconverted to the… Expand

The oral direct thrombin inhibitor (oral DTI) ximelagatran (Exanta, AstraZeneca) is rapidly absorbed and bioconverted to its… Expand

The phase III trial EXPRESS was a randomised, double-blind comparison of two anticoagulant therapies used as prophylaxis against… Expand

There are many well-known drawbacks associated with the currently used antithrombotic agents, warfarin, heparin, and low… Expand

AstraZeneca (formerly Astra) is developing ximelagatran, an orally active thrombin inhibitor and prodrug of melagatran, for the… Expand